Isabella Presch/LinkedIn
Aug 26, 2026, 18:27
Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero
Isabella Presch, Senior Medical Director Rare diseases, Advanced therapies and Pediatrics at Fortrea, shared a post on LinkedIn:
“An important signal from the FDA: not every genome-editing program needs to start from zero.
The new draft guidance highlights how prior knowledge can be responsibly leveraged to advance development while maintaining rigorous standards for quality, safety, and efficacy. Encouraging progress for the future of rare disease innovation.
Potential Strategic Implications for Sponsors:
- Enable faster development across multiple genome-editing programs
- Reduce redundant CMC and nonclinical work
- Encourage early platform planning
- Increase the value of robust platform datasets
- particularly beneficial for rare disease, pediatric, and individualized therapy programs”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 12:24Mercy Lung’aho: When Diet Quality and Nutritional Biomarkers Tell Different Stories
-
Oct 9, 2026, 12:22Eugene Fan: Bridging Therapeutic Breakthroughs and Equitable Thalassaemia Care
-
Oct 9, 2026, 12:14Brittany Busse: A New Focus on Iron Deficiency Before Anemia
-
Oct 9, 2026, 12:13Akshat Jain: A New Textbook Bringing Global Perspectives on Sickle Cell Disease
-
Oct 9, 2026, 12:03Heather Case: Bridging Awareness and Action in Women’s Hemophilia Care
-
Oct 9, 2026, 11:58Brandon Luu: Can Iron Deficiency Cause Fatigue Without Anemia?
-
Oct 9, 2026, 11:51Sumaiya Dickens: Marginal Zone B Cells in Transfusion Medicine and Hemophilia A Research
-
Oct 9, 2026, 11:44Ayyappan V Nair: PRP and Rehabilitation – Can It Help Athletes with Partial Rotator Cuff Tears?
-
Oct 9, 2026, 11:29Jigesha Dholakia: Supporting the Hemophilia Community Through the Unite Walk